Closing RDYN (Replidyne) underperform
I still can't see any future for Replidyne. I think faropenem is in big trouble, and they are way behind a lot of other small caps in their early stage drugs for MRSA and c.diff. But right now, the stock is trading just a few million bucks above cash so I think the steep part of the drop is over. I could watch it continue to trail down over the years, but I'm following a lot of companies right now and I need to concentrate on my high gainers. I don't want to lose my Replidyne CAPS points because I'm not watching closely enough and then it pops on a positive phase II study.